Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.
Authors
Radford, John AIllidge, Timothy M
Counsell, N
Hancock, B
Pettengell, R
Johnson, P
Wimperis, J
Culligan, D
Popova, B
Smith, P
McMillan, A
Brownell, A
Kruger, A
Lister, A
Hoskin, P
O'Doherty, M
Barrington, S
Affiliation
Institute of Cancer Sciences, University of Manchester, and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, ManchesterIssue Date
2015-04-23
Metadata
Show full item recordAbstract
It is unclear whether patients with early-stage Hodgkin's lymphoma and negative findings on positron-emission tomography (PET) after three cycles of chemotherapy with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) require radiotherapy.Citation
Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. 2015, 372 (17):1598-607 N Engl J MedJournal
The New England Journal of MedicineDOI
10.1056/NEJMoa1408648PubMed ID
25901426Type
ArticleLanguage
enISSN
1533-4406ae974a485f413a2113503eed53cd6c53
10.1056/NEJMoa1408648
Scopus Count
Collections
Related articles
- Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.
- Authors: Johnson P, Federico M, Kirkwood A, Fosså A, Berkahn L, Carella A, d'Amore F, Enblad G, Franceschetto A, Fulham M, Luminari S, O'Doherty M, Patrick P, Roberts T, Sidra G, Stevens L, Smith P, Trotman J, Viney Z, Radford J, Barrington S
- Issue date: 2016 Jun 23
- ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma.
- Authors: Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Wells WA, Winter JN, Horning SJ, Dar AR, Shustik C, Stewart DA, Crump M, Djurfeldt MS, Chen BE, Shepherd LE, NCIC Clinical Trials Group., Eastern Cooperative Oncology Group.
- Issue date: 2012 Feb 2
- PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.
- Authors: Borchmann P, Plütschow A, Kobe C, Greil R, Meissner J, Topp MS, Ostermann H, Dierlamm J, Mohm J, Thiemer J, Sökler M, Kerkhoff A, Ahlborn M, Halbsguth TV, Martin S, Keller U, Balabanov S, Pabst T, Vogelhuber M, Hüttmann A, Wilhelm M, Zijlstra JM, Moccia A, Kuhnert G, Bröckelmann PJ, von Tresckow B, Fuchs M, Klimm B, Rosenwald A, Eich H, Baues C, Marnitz S, Hallek M, Diehl V, Dietlein M, Engert A
- Issue date: 2021 Feb
- Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP<sub>escalated</sub> alone or in combination with rituximab (HD18): an open-label, international, randomised phase 3 study by the German Hodgkin Study Group.
- Authors: Borchmann P, Haverkamp H, Lohri A, Mey U, Kreissl S, Greil R, Markova J, Feuring-Buske M, Meissner J, Dührsen U, Ostermann H, Keller U, Maschmeyer G, Kuhnert G, Dietlein M, Kobe C, Eich H, Baues C, Stein H, Fuchs M, Diehl V, Engert A
- Issue date: 2017 Apr
- Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.
- Authors: Engert A, Plütschow A, Eich HT, Lohri A, Dörken B, Borchmann P, Berger B, Greil R, Willborn KC, Wilhelm M, Debus J, Eble MJ, Sökler M, Ho A, Rank A, Ganser A, Trümper L, Bokemeyer C, Kirchner H, Schubert J, Král Z, Fuchs M, Müller-Hermelink HK, Müller RP, Diehl V
- Issue date: 2010 Aug 12